<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872935</url>
  </required_header>
  <id_info>
    <org_study_id>201301793</org_study_id>
    <nct_id>NCT02872935</nct_id>
  </id_info>
  <brief_title>Minimizing Nausea and Vomiting During Spinals for CS</brief_title>
  <official_title>Randomized Double Control Study to Assess the Efficacy of Administering 1 ml of Glycopyrrolate With the Spinal Dose in Minimizing Nausea and Vomiting in Patients Undergoing Cesarean Section Under Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kokila N Thenuwara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      In parturients undergoing Cesarean section under spinal anesthesia, co-loading of 1 liter of
      crystalloids, with placing the spinal, along with administering a phenylephrine infusion and
      glycopyrrolate, enables placing a spinal with minimal perioperative nausea and vomiting and
      good intra and post-operative pain relief.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is as follows: In parturients undergoing Cesarean section under
      spinal anesthesia, co-loading of 1 liter of crystalloids, with placing the spinal, along with
      administering a phenylephrine infusion and glycopyrrolate, enables placing a spinal with
      minimal perioperative nausea and vomiting and good intra and post-operative pain relief.

      The study group will receive phenylephrine infusion [dilution 100micrograms /cc] Rate of
      infusion 50micrograms /hour, approximately 30ml/hour To be started immediately after the
      placement of the spinal anesthetic Patient will also be given .4mg [1cc of glycopyrrolate],
      with the starting of the infusion

      The control group, will receive phenylephrine infusion [dilution 100micrograms /cc] Rate of
      infusion 50micrograms /hour, approximately 30ml/hour To be started immediately after the
      placement of the spinal anesthetic Patient will also be given a placebo [1cc of N saline],
      with the starting of the infusion

      Following the administration of the study drug/placebo, the patient will be monitored for
      severity of nausea , vomiting and pain at 5 minutes intervals from placement of the spinal to
      delivery of the baby, and then at 15 minutes intervals from delivery of the baby till the end
      of the surgery ( the cesarean section)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">May 15, 2015</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Reported Nausea</measure>
    <time_frame>From the administration of the spinal anesthesia to delivery of baby - Total time 90minutes</time_frame>
    <description>Did the subject report nausea? The subject will respond with yes or no.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Vomiting.</measure>
    <time_frame>From the administration of the spinal anesthesia to delivery of baby; Total time 90minutes</time_frame>
    <description>This measure is observed by care team. Reported as vomiting, yes or no.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Placebo: Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1ml of Normal Saline will be given intravenously with the administering of the spinal dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycopyrrolate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose</description>
    <arm_group_label>Glycopyrrolate group</arm_group_label>
    <other_name>Robinul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>1ml of normal saline will be given intravenously with the administration of the spinal dose</description>
    <arm_group_label>Placebo: Normal Saline</arm_group_label>
    <other_name>.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant

          2. American Society of Anesthesiologists risk classification I and II

          3. Age &gt; 18 years

          4. Non-laboring

          5. Patients with elective cesarean sections

        Exclusion Criteria:

          1. Non- English speakers

          2. Height &lt; 4' 11&quot;

          3. BMI &gt;40 Kg/ mm

          4. Antiemetic drug use in the 24 hours prior to cesarean delivery,

          5. Hypertensive diseases of pregnancy

          6. Chronic hypertension receiving antihypertensive treatment

          7. Any other physical or psychiatric condition that may impair their ability to cooperate
             with study data collection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kokila N Thenuwara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carvalho B, Cohen SE, Lipman SS, Fuller A, Mathusamy AD, Macario A. Patient preferences for anesthesia outcomes associated with cesarean delivery. Anesth Analg. 2005 Oct;101(4):1182-7, table of contents.</citation>
    <PMID>16192541</PMID>
  </reference>
  <reference>
    <citation>Abouleish EI, Rashid S, Haque S, Giezentanner A, Joynton P, Chuang AZ. Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia. Anaesthesia. 1999 May;54(5):479-82.</citation>
    <PMID>10995148</PMID>
  </reference>
  <reference>
    <citation>Harmon D, Ryan M, Kelly A, Bowen M. Acupressure and prevention of nausea and vomiting during and after spinal anaesthesia for caesarean section. Br J Anaesth. 2000 Apr;84(4):463-7.</citation>
    <PMID>10823097</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Kokila N Thenuwara</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Do not plan to share data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo: Normal Saline</title>
          <description>1ml of Normal Saline will be given intravenously with the administering of the spinal dose
Normal Saline: 1ml of normal saline will be given intravenously with the administration of the spinal dose</description>
        </group>
        <group group_id="P2">
          <title>Glycopyrrolate Group</title>
          <description>1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
Glycopyrrolate: .2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10">One subject consented but did no proceed with the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo: Normal Saline</title>
          <description>1ml of Normal Saline will be given intravenously with the administering of the spinal dose
Normal Saline: 1ml of normal saline will be given intravenously with the administration of the spinal dose</description>
        </group>
        <group group_id="B2">
          <title>Glycopyrrolate Group</title>
          <description>1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
Glycopyrrolate: .2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported Nausea</title>
        <description>Did the subject report nausea? The subject will respond with yes or no.</description>
        <time_frame>From the administration of the spinal anesthesia to delivery of baby - Total time 90minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Normal Saline</title>
            <description>1ml of Normal Saline will be given intravenously with the administering of the spinal dose
Normal Saline: 1ml of normal saline will be given intravenously with the administration of the spinal dose</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Group</title>
            <description>1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
Glycopyrrolate: .2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Nausea</title>
          <description>Did the subject report nausea? The subject will respond with yes or no.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Vomiting.</title>
        <description>This measure is observed by care team. Reported as vomiting, yes or no.</description>
        <time_frame>From the administration of the spinal anesthesia to delivery of baby; Total time 90minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Normal Saline</title>
            <description>1ml of Normal Saline will be given intravenously with the administering of the spinal dose
Normal Saline: 1ml of normal saline will be given intravenously with the administration of the spinal dose</description>
          </group>
          <group group_id="O2">
            <title>Glycopyrrolate Group</title>
            <description>1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
Glycopyrrolate: .2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Vomiting.</title>
          <description>This measure is observed by care team. Reported as vomiting, yes or no.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo: Normal Saline</title>
          <description>1ml of Normal Saline will be given intravenously with the administering of the spinal dose
Normal Saline: 1ml of normal saline will be given intravenously with the administration of the spinal dose</description>
        </group>
        <group group_id="E2">
          <title>Glycopyrrolate Group</title>
          <description>1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
Glycopyrrolate: .2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kokila Thenuwara</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-384-5876</phone>
      <email>kokila-thenuwara@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

